23 April 2022>: Clinical Research
Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions
Liying Han 1CEF , Guanyong He 1CDE , Yingjie Mei 2CD , Qing Yu 3BF , Minning Zhao 3BF , Fu Luo 4B , Guanxun Cheng 1AEG** , Wen Liang 3AE**DOI: 10.12659/MSM.935307
Med Sci Monit 2022; 28:e935307
Table 2 Patients’ characteristics.
Variable | Value |
---|---|
Median (interquartile range) | |
Age (years) | 70 (65–76) |
tPSA(ng/ml) | 14.30 (7.33–35.11) |
f/t PSA | 0.12 (0.08–0.16) |
PSAD (ng/ml/cm) | 0.20 (0.11–0.52) |
Benign | 52 (62%) |
PCa | 32 (38%) |
GS6 | 7 (21.9%) |
GS7 | 6 (18.8%) |
GS8 | 8 (25%) |
GS9 | 9 (25.1%) |
GS10 | 2 (6.2%) |
tPSA – total prostate-specific antigen; f/t PSA – free/total prostate-specific antigen; PSAD – prostate-specific antigen density; PCa – prostate cancer; GS – Gleason score. |